Next Gen Biotech

Velpanat tablet contains the active components Sofosbuvir and Velpatasvir.  It is used to treat chronic hepatitis C. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). The treatment duration is often shorter than older treatment regimens. The duration can vary depending on factors such as HCV genotype, previous treatment history, and the presence of liver cirrhosis. Successful treatment with Velpanat tablet can significantly reduce liver inflammation and fibrosis caused by HCV infection. By achieving viral eradication, the risk of developing liver cirrhosis, liver failure, and hepatocellular carcinoma (a type of liver cancer) can be substantially reduced.

If you have a known allergy or hypersensitivity to Velpanat tablet or any of the components of the medication, you should not take it. The safety and efficacy of sofosbuvir and velpatasvir combination therapy have not been established in children under 18. Its use in the pediatric population is currently limited. It is recommended to use alternative treatment options or adjust the dosage in these cases. 

Velasof tablet contains the active components Sofosbuvir and Velpatasvir.  It is used to treat chronic hepatitis C. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). The treatment duration is often shorter than older treatment regimens. The duration can vary depending on factors such as HCV genotype, previous treatment history, and the presence of liver cirrhosis. Successful treatment with Velasof tablet can significantly reduce liver inflammation and fibrosis caused by HCV infection. By achieving viral eradication, the risk of developing liver cirrhosis, liver failure, and hepatocellular carcinoma (a type of liver cancer) can be substantially reduced.

If you have a known allergy or hypersensitivity to Velasof tablet or any of the components of the medication, you should not take it. The safety and efficacy of sofosbuvir and velpatasvir combination therapy have not been established in children under 18. Its use in the pediatric population is currently limited. It is recommended to use alternative treatment options or adjust the dosage in these cases. 

Sofovir 400mg Tablet contains the active component as Sofosbuvir. It is a direct-acting antiviral medication used to treat hepatitis C virus (HCV) infection. This medication is often combined with other antiviral drugs to form a regimen that can effectively eliminate HCV from the body. Sofovir 400mg Tablet has significantly shortened the duration of HCV treatment compared to older therapies. It is effective against multiple genotypes of the hepatitis C virus. This broad-spectrum activity makes it a versatile treatment option that can be used for a wide range of patients infected with different HCV genotypes. 

Patients have generally well-tolerated with this medication, with few serious side effects reported. Sofovir 400mg Tablet should not be used in individuals with known hypersensitivity or allergic reactions to it or its components. This medication is primarily eliminated through the kidneys. Therefore, individuals with severe renal impairment may require dosage adjustments. It is not approved for use in children under the age of 18.

Sovihep V tablet contains the active components Sofosbuvir and Velpatasvir.  It is used to treat chronic hepatitis C. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). The treatment duration is often shorter than older treatment regimens. The duration can vary depending on factors such as HCV genotype, previous treatment history, and the presence of liver cirrhosis. Successful treatment with Sovihep V tablet can significantly reduce liver inflammation and fibrosis caused by HCV infection. By achieving viral eradication, the risk of developing liver cirrhosis, liver failure, and hepatocellular carcinoma (a type of liver cancer) can be substantially reduced.

If you have a known allergy or hypersensitivity to Sovihep V tablets or any of the components of the medication, you should not take it. The safety and efficacy of sofosbuvir and velpatasvir combination therapy have not been established in children under 18. Its use in the pediatric population is currently limited. It is recommended to use alternative treatment options or adjust the dosage in these cases. Sovihep V price is differ from vendor to vendor. Sovihep V substitute Sofosbuvir 400 mg and Velpatasvir 100 mg. Sovihep V Tablet price varies by retailer and location. You can buy Sovihep V Tablet online.